JP2016525095A5 - 環状ポリペプチド - Google Patents
環状ポリペプチド Download PDFInfo
- Publication number
- JP2016525095A5 JP2016525095A5 JP2016524890A JP2016524890A JP2016525095A5 JP 2016525095 A5 JP2016525095 A5 JP 2016525095A5 JP 2016524890 A JP2016524890 A JP 2016524890A JP 2016524890 A JP2016524890 A JP 2016524890A JP 2016525095 A5 JP2016525095 A5 JP 2016525095A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclic
- disease
- receptor
- cyclic polypeptides
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004122 cyclic group Chemical group 0.000 title claims 12
- 229920001184 polypeptide Polymers 0.000 title claims 12
- 230000003281 allosteric Effects 0.000 claims 6
- 230000000051 modifying Effects 0.000 claims 5
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 1
- 206010028003 Motor neurone disease Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003415 peat Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (12)
- 配列番号４からなる環状ポリペプチド。
- 治療または診断における使用のための、請求項１に記載の環状ポリペプチド。
- 神経変性疾患の治療、改善または予防における使用のための、請求項１に記載の環状ポリペプチド。
- 前記神経変性疾患は、アルツハイマー病；パーキンソン病；ハンチントン病；運動ニューロン疾患；脊髄小脳１型、２型、および３型；筋萎縮性側索硬化症（ＡＬＳ）；ならびに前頭側頭型認知症からなる群より選択される、請求項３に記載の環状ポリペプチド。
- 前記神経変性疾患はアルツハイマー病である、請求項４に記載の環状ポリペプチド。
- α７ニコチン性受容体の選択的アロステリックモジュレーターである；および／またはβアミロイドの結合をアウトコンピート（ｏｕｔｃｏｍｐｅｔｅ）する；および／または単離もしくは精製されている、請求項２〜５のいずれか１項に記載の環状ポリペプチド。
- 請求項１に記載の環状ポリペプチドを含む、受容体アロステリックモジュレーター。
- 請求項１で定義される、受容体アロステリックモジュレーターとしての使用のための、環状ポリペプチド。
- 治療上有効な量の請求項１に記載の環状ポリペプチド、または請求項７に記載の受容体アロステリックモジュレーターと、必要に応じて、薬学的に許容される賦形剤と、を含む薬剤組成物。
- 治療上有効な量の請求項１に記載の環状ポリペプチド、または請求項７に記載の受容体アロステリックモジュレーターと、薬学的に許容される賦形剤と、を組み合わせることを含む、請求項９に記載の薬剤組成物の製造方法。
- α７ニコチン性受容体を探索するためのｉｎ ｖｉｔｒｏまたはｅｘ ｖｉｖｏの分析方法における、請求項１に記載の環状ポリペプチドの使用。
- 前記方法は、α７ニコチン性受容体のアロステリック部位を調査することを含み、必要に応じて、前記方法はα７ニコチン性受容体を通じたカルシウムのさらなる流入を防止することを含む、請求項１１に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1312279.1A GB2516045A (en) | 2013-07-09 | 2013-07-09 | Neurodegenerative disorders |
| GB1312279.1 | 2013-07-09 | ||
| PCT/GB2014/052041 WO2015004430A1 (en) | 2013-07-09 | 2014-07-04 | Neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525095A JP2016525095A (ja) | 2016-08-22 |
| JP2016525095A5 true JP2016525095A5 (ja) | 2017-07-27 |
| JP6647199B2 JP6647199B2 (ja) | 2020-02-14 |
Family
ID=49033534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524890A Active JP6647199B2 (ja) | 2013-07-09 | 2014-07-04 | 環状ポリペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10053677B2 (ja) |
| EP (1) | EP3019591B1 (ja) |
| JP (1) | JP6647199B2 (ja) |
| KR (1) | KR102436886B1 (ja) |
| CN (1) | CN105531383B (ja) |
| AU (2) | AU2014289001C1 (ja) |
| BR (1) | BR112016000565B1 (ja) |
| CA (1) | CA2917389C (ja) |
| ES (1) | ES2650543T3 (ja) |
| GB (1) | GB2516045A (ja) |
| MX (1) | MX2016000095A (ja) |
| WO (1) | WO2015004430A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2538947A (en) * | 2014-12-19 | 2016-12-07 | Neuro-Bio Ltd | Cancer |
| GB201613999D0 (en) * | 2016-08-16 | 2016-09-28 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| GB2587211A (en) * | 2019-09-18 | 2021-03-24 | Neuro Bio Ltd | Animal model |
| GB202004803D0 (en) * | 2020-04-01 | 2020-05-13 | Neuro Bio Ltd | Skin |
| GB202004804D0 (en) * | 2020-04-01 | 2020-05-13 | Neuro Bio Ltd | Skin |
| GB202014080D0 (en) * | 2020-09-08 | 2020-10-21 | Neuro Bio Ltd | Down's syndrome |
| BR112023012422A2 (pt) | 2021-01-24 | 2023-12-12 | Michael David Forrest | Inibidores da atp sintase - usos cosmético e terapêutico |
| KR20230165640A (ko) | 2022-05-27 | 2023-12-05 | 가천대학교 산학협력단 | 혈액 엑소좀 단백질 양 및 아세틸콜린 에스터레이즈 활성도에 기초한 파킨슨 병 진단 방법 |
| WO2024052650A1 (en) | 2022-09-08 | 2024-03-14 | Neuro-Bio Ltd | Lateral flow device for diagnosing alzheimer's disease using the t14 peptide |
| GB202306078D0 (en) | 2023-04-25 | 2023-06-07 | Neuro Bio Ltd | Neurodegenerative disorders |
| GB202306126D0 (en) * | 2023-04-26 | 2023-06-07 | Neuro Bio Ltd | Treatment of rapamycin-sensitive conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5777073A (en) * | 1994-12-12 | 1998-07-07 | The Salk Institute For Biological Studies | Cyclic CRF antagonist peptides |
| DE69736976T2 (de) * | 1996-03-29 | 2007-10-18 | Trustees Of Boston University, Boston | Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden |
| IL131707A0 (en) * | 1999-05-31 | 2001-03-19 | Yissum Res Dev Co | Acetylcholinesterase-derived peptides and uses thereof |
| GB9930825D0 (en) * | 1999-12-30 | 2000-02-16 | Synaptica Limited | Animal models for neurodegenerative disease |
| US20030092613A1 (en) * | 2000-08-14 | 2003-05-15 | Lee Daniel H. S. | Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides |
| CA2825519A1 (en) * | 2011-02-03 | 2012-09-08 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
-
2013
- 2013-07-09 GB GB1312279.1A patent/GB2516045A/en not_active Withdrawn
-
2014
- 2014-07-04 BR BR112016000565-1A patent/BR112016000565B1/pt active IP Right Grant
- 2014-07-04 EP EP14736948.2A patent/EP3019591B1/en active Active
- 2014-07-04 US US14/903,589 patent/US10053677B2/en active Active
- 2014-07-04 CN CN201480039512.7A patent/CN105531383B/zh active Active
- 2014-07-04 JP JP2016524890A patent/JP6647199B2/ja active Active
- 2014-07-04 ES ES14736948.2T patent/ES2650543T3/es active Active
- 2014-07-04 CA CA2917389A patent/CA2917389C/en active Active
- 2014-07-04 MX MX2016000095A patent/MX2016000095A/es active IP Right Grant
- 2014-07-04 KR KR1020167003432A patent/KR102436886B1/ko active IP Right Grant
- 2014-07-04 WO PCT/GB2014/052041 patent/WO2015004430A1/en active Application Filing
- 2014-07-04 AU AU2014289001A patent/AU2014289001C1/en active Active
-
2018
- 2018-08-17 US US15/999,129 patent/US11091747B2/en active Active
- 2018-11-08 AU AU2018260893A patent/AU2018260893B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| WO2010115843A3 (en) | Pharmaceutical composition | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| JP2016512425A5 (ja) | ||
| RU2011152816A (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ Tau pS422 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГОЛОВНОГО МОЗГА | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| WO2017081211A3 (en) | Antigen-binding polypeptides directed against cd38 | |
| MD3261720T2 (ro) | Anticorpi anti-Tau și utilizările acestora | |
| JP2008508859A5 (ja) | ||
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MY183989A (en) | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| JP2012115277A5 (ja) | ||
| UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| DK1940826T3 (da) | Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4 | |
| WO2017184873A3 (en) | Compositions and methods related to the methylation of histone h1.0 protein | |
| TW200801035A (en) | Peptide vaccine for producing anti-amyloid beta peptide antibody | |
| JP2019513752A5 (ja) | ||
| JP2013533273A5 (ja) | ||
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| MD20160102A2 (ro) | Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei | |
| JP2014516535A5 (ja) | ||
| JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل |